DNA-guided protein crystals could accelerate drug discovery

For more than half a century, protein crystallization has been one of the great bottlenecks of structural biology. Scientists have relied on a mixture of expertise, patience, and often considerable luck to persuade proteins to form crystals suitable for X-ray analysis. Yet understanding the three-dimensional structure of proteins remains fundamental to modern medicine, enabling researchers to identify drug targets, understand disease mechanisms, and engineer novel biological systems.

Now, researchers at Northwestern University have reported a breakthrough that could change this process fundamentally. Rather than depending on proteins to self-assemble through unpredictable molecular interactions, the team has used DNA as a programmable construction tool to direct proteins into precisely engineered crystalline structures. The work was published in Science Advances on July 29, 2026.

While the scientific achievement is significant in its own right, the broader implications may be even more important. The technology points toward a future where the crystallization of proteins becomes predictable, programmable, and potentially adaptable to a wide range of industrial and medical applications.

A persistent challenge in biology

Proteins are among the most important molecules in living organisms. They catalyse chemical reactions, transport substances, regulate cellular functions, and form the structural basis of tissues. To understand how proteins perform these tasks, scientists often need to determine their atomic structure.

The gold-standard technique for this has long been X-ray crystallography. However, before structural analysis can occur, proteins must first be grown into crystals. This remains a challenging and often frustrating process because proteins vary enormously in their chemistry and physical characteristics. Many proteins simply refuse to crystallize under conventional conditions. The Northwestern researchers sought to address this challenge by borrowing a molecule more commonly associated with genetics than with materials science: DNA.

Using DNA as molecular glue

The principle behind the approach is elegant. DNA possesses highly predictable binding properties. Its four nucleotide bases pair in specific combinations, allowing scientists to design sequences that selectively bind to one another with remarkable precision. Led by nanotechnology pioneer Chad Mirkin, the research team attached short strands of DNA to proteins. These DNA strands then acted as programmable molecular connectors, pulling proteins together in predetermined orientations and positions. Instead of relying on random molecular contacts, the assembly process became intentional and controllable.

According to the study, the resulting protein crystals exhibited atomic-level order while also possessing unusual flexibility. This finding challenges a long-standing assumption in crystallography that highly ordered crystals must be relatively rigid structures. Even more striking, the researchers successfully generated more than 1,000 protein crystals and determined the structures of 28 distinct DNA-protein designs, demonstrating that the method is reproducible rather than a one-off laboratory success.

The most immediate impact may be on pharmaceutical research and development. Many therapeutic programmes fail because researchers lack detailed information about the molecular targets involved in disease. Improved access to high-resolution protein structures could accelerate structure-based drug design, allowing investigators to identify binding sites, optimize candidate compounds, and better understand biological pathways.

The biotechnology sector is increasingly focused on complex targets such as membrane proteins, engineered enzymes, and multi-protein complexes. These systems are often difficult to crystallize using conventional techniques. A programmable crystallization platform could expand the range of proteins available for structural investigation and reduce development timelines. For pharmaceutical companies operating in a competitive environment where speed to market is increasingly critical, any technology that simplifies structural characterization could offer a significant advantage.

The work extends well beyond protein structure determination. The researchers demonstrated that DNA-directed crystals can be engineered with tuneable physical properties. Because DNA length, sequence, and placement can be modified, the architecture of the resulting crystal can also be altered. This opens possibilities for designing materials with specific mechanical, chemical, or biological characteristics.

Potential applications highlighted by the research include:

• Advanced biosensors
• Targeted drug delivery systems
• Bioelectronic devices
• Soft robotic materials
• Enzyme-based catalytic platforms
• Programmable biomaterials

In effect, proteins could become customizable building blocks for entirely new material systems.

The breakthrough also reflects the maturation of a scientific concept first pioneered by Mirkin’s laboratory in the 1990s. Earlier work demonstrated that DNA could function as a programmable bonding agent for nanoparticles, enabling the construction of complex nanoscale architectures.

The new study extends that concept into biology. Instead of synthetic nanoparticles, DNA is now being used to organize proteins—nature’s own nanoscale machines—into precisely controlled structures. This convergence of nanotechnology, molecular biology, and materials science illustrates how disciplines once viewed as separate are increasingly merging to create new technological capabilities.

What comes next?

Like many breakthrough technologies, practical implementation will require further development. Researchers will need to demonstrate that the method can be applied to a broader range of proteins and that it can be integrated into workflows used routinely by academic laboratories and pharmaceutical companies. Nevertheless, the proof-of-concept is compelling. By transforming protein crystallization from an exercise in trial and error into a design-driven process, the Northwestern team may have opened a new chapter in structural biology.

More importantly, the work suggests a future where DNA is used not merely as the carrier of genetic information but as a programmable engineering material capable of assembling complex biological systems with atomic precision. Such advances could ultimately influence fields ranging from pharmaceutical development and diagnostics to advanced manufacturing and robotics.